A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's (NVO ...

Preview in new tab Pharmaceutical giants Eli Lilly ($LLY) and Novo Nordisk ($NVO) are engaged in a head-to-head battle to ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

Published in the New England Journal of Medicine, the study followed 751 obese Americans to test the efficacy ... of either Zepbound, Eli Lilly’s obesity drug, or Novo Nordisk’s Wegovy.

While tirzepatide won out in what Aronne said many view as “a drag race of efficacy ... tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or ...

Zepbound Beats Wegovy for Weight Loss in First Head-To ... While tirzepatide won out in what Aronne said many view as “a drag race of efficacy,” both are important tools for treating obesity ...